Does holding at 60 mg for two weeks before escalating reduce nausea?

Setup, so nobody has to ask: 60 mg · two weeks · nausea.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

Worth being precise here: the steady-state arithmetic is worth doing once, because it explains most of what people find confusing about weekly dosing.

Missing a dose by three days on a weekly schedule takes the trough down by less than a factor of 1.35, which is well inside the variation you would see between two on-time weeks. Missing it by five or more days is where the label instructions start to differ between agents, and the reason is how close the next scheduled dose is rather than any mechanistic threshold.

The maintenance question turns on what you are maintaining. If the objective is weight maintenance, the withdrawal-extension data suggests that a fraction of the therapeutic dose retains a substantial fraction of the effect. If the objective is the cardiovascular or renal endpoint, the trials that demonstrated those endpoints used the full dose, and extrapolating downward is not supported by anything.

The limitation of all trial-derived dosing reasoning is that trial populations were selected, monitored and supported in ways that do not resemble anyone reading this.

If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.

Stated carefully, four weeks is not a magic number, it is approximately five half-lives, which is the interval over which a weekly compound reaches steady state after a dose change. Escalating faster means escalating onto a rising concentration.

Where the label ladders differ between agents, the differences track the potency ratio and the tolerability profile rather than anything deeper. It is worth reading the ladders side by side once, because the pattern — small starting dose, four-week steps, a defined maintenance range and a defined maximum — is identical in structure across the class.

Put another way, the argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.

The pharmacokinetics of the acylated agonists are well described: absorption from the subcutaneous depot is slow and rate-limiting, the elimination half-life is approximately one week, and steady state is reached in four to five weeks. Every dosing question in this section follows from those three facts.

Read the actual prescribing information for the agent in question. It is short, specific, and more reliable than any summary of it.

Specifically, the titration schedule is a tolerability instrument, not an efficacy one. Nothing in the ladder is there to make the compound work better; every step exists to make the gastrointestinal adverse-event curve survivable.

Holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.

In practice, what the label says and what the trial protocols permitted are different documents, and the difference is instructive: protocols generally allowed a step to be delayed or reversed for intolerance, and a substantial minority of participants used that provision.

Escalating in response to a plateau is a specific and common error of reasoning. A plateau after four to six months is the expected trajectory in every trial in the class — the curve flattens because energy expenditure falls with mass, not because the receptor stopped working. A dose step may still be reasonable; "the loss stopped" is not by itself the reason.

Write down in advance what would make you hold a step, because deciding that in the middle of a bad week is not when you are at your most analytical.